Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bleximenib |
| Synonyms | |
| Therapy Description |
Bleximenib inhibits the interaction between menin and MLL, leading to decreased expression of target genes, which potentially inhibits proliferation of tumor cells harboring KMT2A rearrangements or NPM1 mutations (PMID: 38905635). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bleximenib | JNJ 75276617|JNJ75276617|JNJ-75276617 | MEN1-KMT2A Inhibitor 8 | Bleximenib inhibits the interaction between menin and MLL, leading to decreased expression of target genes, which potentially inhibits proliferation of tumor cells harboring KMT2A rearrangements or NPM1 mutations (PMID: 38905635). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04811560 | Phase Ib/II | Bleximenib | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) (cAMeLot-1) | Recruiting | USA | ISR | GBR | FRA | ESP | CAN | BRA | AUS | 4 |